77 related articles for article (PubMed ID: 21289525)
1. Association of hot flushes with ghrelin and adipokines in early versus late postmenopausal women.
Karim R; Dang HM; Hodis HN; Stanczyk FZ; Brinton RD; Mack WJ
Menopause; 2020 May; 27(5):512-518. PubMed ID: 32049929
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial.
Hale MJ; Howell A; Dowsett M; Cuzick J; Sestak I
Breast; 2020 Dec; 54():216-221. PubMed ID: 33160147
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene for the prevention of postmenopausal osteoporosis.
Gennari L; Merlotti D; De Paola V; Martini G; Nuti R
Ther Clin Risk Manag; 2008 Dec; 4(6):1229-42. PubMed ID: 19337430
[TBL] [Abstract][Full Text] [Related]
4. The effect of resistance training in reducing hot flushes in post-menopausal women: A meta-analysis.
Choudhry DN; Saleem S; Hatim S; Irfan R
J Bodyw Mov Ther; 2024 Jul; 39():335-342. PubMed ID: 38876649
[TBL] [Abstract][Full Text] [Related]
5. FDA approves first-in-class NK3 receptor antagonist for hot flushes.
Mullard A
Nat Rev Drug Discov; 2023 Jul; 22(7):526. PubMed ID: 37208488
[No Abstract] [Full Text] [Related]
6. Hormone therapy for sexual function in perimenopausal and postmenopausal women.
Lara LA; Cartagena-Ramos D; Figueiredo JB; Rosa-E-Silva ACJ; Ferriani RA; Martins WP; Fuentealba-Torres M
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD009672. PubMed ID: 37619252
[TBL] [Abstract][Full Text] [Related]
7. Effects of Bazedoxifene/Vitamin D Combination Therapy on Serum Vitamin D Levels and Bone Turnover Markers in Postmenopausal Women with Osteopenia: A Randomized Controlled Trial.
Jeong C; Ha J; Yoo JI; Lee YK; Kim JH; Ha YC; Min YK; Byun DW; Baek KH; Chung HY
J Bone Metab; 2023 May; 30(2):189-199. PubMed ID: 37449351
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers.
Yeun JS; Kan HS; Lee M; Kim N; Oh TY; Nam SK; Choi YS; Kwon IS; Hong JH
Transl Clin Pharmacol; 2020 Jun; 28(2):102-108. PubMed ID: 32656161
[TBL] [Abstract][Full Text] [Related]
9. Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.
Iliodromiti S; Wang W; Lumsden MA; Hunter MS; Bell R; Mishra G; Hickey M
BJOG; 2020 Feb; 127(3):320-333. PubMed ID: 31621155
[TBL] [Abstract][Full Text] [Related]
10. Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.
Vignozzi L; Malavolta N; Villa P; Mangili G; Migliaccio S; Lello S
J Endocrinol Invest; 2019 May; 42(5):609-618. PubMed ID: 30456623
[No Abstract] [Full Text] [Related]
11. The Tissue-Selective Estrogen Complex: A Review of Current Evidence.
Pazhekattu R; Lau AN; Adachi JD
Rheumatol Ther; 2015 Jun; 2(1):47-58. PubMed ID: 27747497
[TBL] [Abstract][Full Text] [Related]
12. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.
Rossini M; Lello S; Sblendorio I; Viapiana O; Fracassi E; Adami S; Gatti D
Drug Des Devel Ther; 2013; 7():601-10. PubMed ID: 23901263
[TBL] [Abstract][Full Text] [Related]
13. Nuclear receptors and their selective pharmacologic modulators.
Burris TP; Solt LA; Wang Y; Crumbley C; Banerjee S; Griffett K; Lundasen T; Hughes T; Kojetin DJ
Pharmacol Rev; 2013 Apr; 65(2):710-78. PubMed ID: 23457206
[TBL] [Abstract][Full Text] [Related]
14. Bazedoxifene: literature data and clinical evidence.
Lello S; Brandi ML; Minisola G; Minisola S; Genazzani AR
Clin Cases Miner Bone Metab; 2011 Sep; 8(3):29-32. PubMed ID: 22461826
[TBL] [Abstract][Full Text] [Related]
15. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
[TBL] [Abstract][Full Text] [Related]
17. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.
Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E
Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006
[TBL] [Abstract][Full Text] [Related]
18. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
